Studieoverzicht - 2018-03 TRAIN-3

 
Number 2018-03 TRAIN-3
Nickname TRAIN-3
Status Submitted (METC) Date: 18-09-2018
Inclusion closed
Other study number(s)
Participating parties/groups
Full title Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: the TRAIN-3 study
Phase and type single arm
Age ≥18 woman / man
Menopausal status Not applicable
Indication Neoadjuvant
Subindication HER2+, any HR
Target sample size 462
Actual accrual 0 Date: 03-09-2018
Estimated study completion date 31-12-2022
CCMO approval Date: Nr: NL66887.038.18
EudraCT nr.
Trial Register
METC approval Date: METC: Nederlands Kanker Instituut Nr:
Amendments Date:
KWF-CKS approval Not applicable Date: Nr:
News item
Website
Sponsor BOOG Study Center
Principal Investigator(s) Dr. GS Sonke MD PhD (The Netherlands Cancer Institute)
Study manager Dr. A.E. van Leeuwen-Stok (BOOG Study Center)

Study coördinator:
A. van der Voort, MD
T 020-5126169

Central datamanagement and randomization Randomization:
NKI Data Center, Trial Office
P.O. Box 90203
1006 BE Amsterdam
Phone +31 20 512 2668
Fax +31 20 512 2679
E-mail trial@nki.nl

Central contact Data Centre:
I. Mandjes BSc
NKI Data Center
Phone 0031 20 512 2880
E-mail i.mandjes@nki.nl
Monitoring NKI Data Center
Local datamanagement
Funding
Extra Contracts & finances: BOOG Study Center (info@boogstudycenter.nl)

Design:
Objectives:
Endpoints:
Main eligibility criteria:
Documents (public):

Protocol synopsis

Documents (protected):
In order to see this content you need to be logged on.

Login.

Back